Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02313584|
Recruitment Status : Unknown
Verified December 2014 by Young-Hoon Kim, Korea University Anam Hospital.
Recruitment status was: Not yet recruiting
First Posted : December 10, 2014
Last Update Posted : December 10, 2014
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Thromboembolism||Drug: dabigatran Drug: placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||464 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||September 2016|
|Estimated Study Completion Date :||September 2017|
Active Comparator: Short Group
The patients taking dabigatran for 1 month after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
Placebo Comparator: Conventional Group
The patients taking dabigatran for 2 months after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
- The rate of thromboembolic events [ Time Frame: 2 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02313584
|Contact: Young-Hoon Kimfirstname.lastname@example.org|